The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
Clémenson, Céline, Jouannot, Erwan, Merino-Trigo, Ana, Rubin-Carrez, Chantal, Deutsch, EricVolume:
31
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-012-9852-4
Date:
April, 2013
File:
PDF, 533 KB
english, 2013